Drug
SHR-A1811 Injection
SHR-A1811 Injection is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
recruiting375%
active_not_recruiting125%
Recent Activity
4 active trials
Showing 4 of 4
active_not_recruitingphase_3
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06057610
recruitingphase_2
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
NCT07051486
recruitingphase_2
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT07102901
recruitingphase_2
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
NCT06340230
Clinical Trials (4)
Showing 4 of 4 trials
NCT06057610Phase 3
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT07051486Phase 2
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
NCT07102901Phase 2
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT06340230Phase 2
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4